European Hematology Association (EHA), 2024

Authors

Laurent Pascal ¹, Alice Wolfromm ², Alexandre Morel ³, Katell Le Dû ⁴, Marine Seigneuret ¹, Pénélope Lacombe ³, Jessica Pinto ², Vanessa Beau ⁵, Anne Banos ⁵, Sophie Bernard ⁵, Marie Vercruyssen ², Juliette Fanton-D'andon ⁶, Élodie Nouhaud ⁶, Charles Ferté ⁶, Arlindo Ferreira ^[6,7], Maximilien Authemann ⁶, Julie Gay ⁵.

‍

Affiliation

1. Groupement des Hôpitaux de l'Institut Catholique de Lille ; 2. Institut Jules Bordet ; 3. Hôpital Privé d'Antony ; 4. Hôpital Privé du Confluent ; 5. Centre Hospitalier de la Côte Basque ; 6. Resilience ; 7. Universidade Católica Portuguesa.

‍

Introduction

Symptoms frequently experienced by patients undergoing anti-cancer treatment are a major cause of morbidity and acute complications. However, they remain insufficiently detected and are often underestimated by healthcare professionals^[1].

By enabling earlier management of patient-reported outcomes (ePROs), medical remote monitoring delivers significant clinical benefits, such as the reduction of severe toxicities, emergency room visits, and unplanned hospitalizations, as well as the improvement of quality of life and the extension of treatment duration.

For this reason, the ESMO (European Society for Medical Oncology) recommends medical remote monitoring for cancer patients^[2]. This study presents the deployment of medical remote monitoring for patients undergoing treatment in hemato-oncology.

‍

Poster presented at the 2024 EHA (European Hematology Association) Congress.

‍

Sources

1. Laugsand EA, Sprangers MA, Bjordal K, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes. 2010;8:104. Published 2010 Sep 21.

‍

2. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. *Ann Oncol*. 2022;33(9):878-892.